San Diego, CA, United States of America

Mark C Glassy

USPTO Granted Patents = 13 

 

Average Co-Inventor Count = 3.1

ph-index = 4

Forward Citations = 64(Granted Patents)


Company Filing History:


Years Active: 1986-2021

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Mark C Glassy: Innovator in Drug Delivery and Antibody Technology

Introduction

Mark C Glassy is a prominent inventor based in San Diego, CA. He has made significant contributions to the fields of drug delivery and antibody technology, holding a total of 13 patents. His work focuses on enhancing the delivery of drugs to the brain and developing antibodies for treating hyperproliferative disorders.

Latest Patents

Among his latest patents, one notable invention is related to the enhanced delivery of drugs to the brain. This patent provides compositions and methods involving antibodies or antibody fragments capable of crossing the blood-brain barrier. Another significant patent involves antibodies that recognize hyperproliferative cells, which are crucial for treating disorders such as neoplasia. These inventions highlight his commitment to advancing medical science and improving treatment options.

Career Highlights

Throughout his career, Mark has worked with esteemed institutions, including the University of California and Shantha West, Inc. His innovative research has paved the way for new therapeutic approaches, particularly in the realm of cancer treatment and neurological disorders.

Collaborations

Mark has collaborated with notable professionals in his field, including Harold H Handley and Yoshihide Hagiwara. These partnerships have further enriched his research and contributed to the success of his inventions.

Conclusion

Mark C Glassy stands out as a dedicated inventor whose work has the potential to transform medical treatments. His innovative patents and collaborations reflect his significant impact on the fields of drug delivery and antibody technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…